Scientists comment on MHRA saying ‘Donanemab licensed for treatment of Alzheimer’s disease in some adults’, and NICE draft guidance saying … read more
A perspective article published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association looks at challenges for new Alzheimer’s drugs. … read more
Scientist comment on the EMA decision on the use of lecanemab for Alzheimer’s disease. Prof Robert Howard, Professor of … read more
Scientists react to news that the FDA are delaying a decision on the Alzheimer’s drug Donanemab. Prof Robert Howard, … read more
Results from Eli Lilly’s TRAILBLAZER-ALZ 2 Randomized Clinical Trial looking at the use of donanemab in early symptomatic Alzheimer’s disease … read more
By Fiona Fox This blog contains the thoughts of the author rather than representing the work or policy of the … read more
A press release from Eli Lilly states that their antibody treatment, donanemab, significantly slowed cognitive and functional decline in phase … read more
A conference abstract (not a published paper) presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2022 compares the … read more
Results of the phase 3 trial of lecanemab for early Alzheimer’s disease has been published in New England Journal of … read more
The U.S. Food & Drug Administration (FDA) has today approved aducanumab (Aduhelm) to treat patients with Alzheimer’s disease. Prof … read more